334 related articles for article (PubMed ID: 37569888)
1. A Brief Review on the Potential of Psychedelics for Treating Alzheimer's Disease and Related Depression.
Pilozzi A; Foster S; Mischoulon D; Fava M; Huang X
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569888
[TBL] [Abstract][Full Text] [Related]
2. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
[TBL] [Abstract][Full Text] [Related]
3. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
4. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.
Holze F; Singh N; Liechti ME; D'Souza DC
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886
[TBL] [Abstract][Full Text] [Related]
5. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
6. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
7. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into psychedelic drug action.
Slocum ST; DiBerto JF; Roth BL
J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
[TBL] [Abstract][Full Text] [Related]
9. A Brief Historical Overview of Psychedelic Research.
Geyer MA
Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):464-471. PubMed ID: 38000715
[TBL] [Abstract][Full Text] [Related]
10. Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.
Garcia-Romeu A; Darcy S; Jackson H; White T; Rosenberg P
Curr Top Behav Neurosci; 2022; 56():287-317. PubMed ID: 34734390
[TBL] [Abstract][Full Text] [Related]
11. Mescaline: The forgotten psychedelic.
Vamvakopoulou IA; Narine KAD; Campbell I; Dyck JRB; Nutt DJ
Neuropharmacology; 2023 Jan; 222():109294. PubMed ID: 36252614
[TBL] [Abstract][Full Text] [Related]
12. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
13. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
14. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
15. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies.
Calleja-Conde J; Morales-García JA; Echeverry-Alzate V; Bühler KM; Giné E; López-Moreno JA
Addict Biol; 2022 Nov; 27(6):e13229. PubMed ID: 36301215
[TBL] [Abstract][Full Text] [Related]
16. Psychedelics and mental health: a population study.
Krebs TS; Johansen PØ
PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
[TBL] [Abstract][Full Text] [Related]
17. Psychedelic Drugs in Biomedicine.
Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
[TBL] [Abstract][Full Text] [Related]
18. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849
[TBL] [Abstract][Full Text] [Related]
19. Dosing Psychedelics and MDMA.
Liechti ME; Holze F
Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
[TBL] [Abstract][Full Text] [Related]
20. Role of Psychedelics in Treatment-Resistant Depression.
Kamal S; Jha MK; Radhakrishnan R
Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
